AMPX vs CDLR

AMPX exhibits weak deterministic health with a Piotroski F-Score of 1/9, indicating severe financial distress and poor operational efficiency, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite this, the stock is trading at a premium valuation (Forward P/E: 182.91, Price/Sales: 33.78) driven by extraordinary revenue growth (137.4% YoY) and strong earnings surprises (average +52.81% over last 4 quarters). Analyst consensus is strongly bullish with a 'strong_buy' rating and a $20.00 target, reflecting high growth expectations. Insider selling activity (8 transactions, $37.78M) introduces bearish sentiment, but the company's technical trend and recent price momentum suggest strong market confidence. The Graham Number and intrinsic value are unavailable, indicating no defensive margin of safety.

CDLR presents a compelling deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a significant valuation gap, with the current price ($26.38) trading well below both the Graham Number ($40.93) and the growth-based Intrinsic Value ($109.44). The company exhibits elite profitability with a 45.17% profit margin and explosive revenue growth of 95% YoY. While technical trends (10/100) and insider sentiment (40/100) are currently bearish, the fundamental disconnect suggests a strong margin of safety. The risk profile is balanced by a healthy ROE of 20.47% and a manageable Debt/Equity ratio of 1.08.